Tocilizumab

Major

Tocilizumab Clindamycin ANTIROBE Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Colchicine Colcrys Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Abatacept Injection Orencia An increased risk of infection Details Tocilizumab Abemaciclib Verzenio Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Acalabrutinib Calquence Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Anifrolumab-Fnia Injection Saphnelo Additive effects due to duplication of therapy Details Tocilizumab Atorvastatin Atorvaliq Reduced atorvastatin exposure and reduced efficacy of atorvastatin Details Tocilizumab Abatacept Orencia Explained An increased risk of infection Details Tocilizumab Axitinib Inlyta Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Baricitinib Olumiant An increased risk of infection Details Tocilizumab Bosutinib Bosulif Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Brigatinib Alunbrig Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Clindamycin Injection ANTIROBE Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Clindamycin Topical C/T/S® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Clindamycin Vaginal Cleocin Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Cobimetinib Cotellic Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Cyclosporine Injection Atopica Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Cyclosporine Ophthalmic Cequa Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Dasatinib Phyrago Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Dihydroergotamine Nasal Spray Migranal Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Docetaxel Beizray Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Docetaxel Injection Beizray Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Dofetilide Tikosyn Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Entrectinib Rozlytrek Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Estradiol Delestrogen Reduced oral contraceptives exposure and reduced efficacy of oral contraceptives Details Tocilizumab Estradiol Topical Divigel Reduced oral contraceptives exposure and reduced efficacy of oral contraceptives Details Tocilizumab Estradiol Transdermal Patch Alora® Reduced oral contraceptives exposure and reduced efficacy of oral contraceptives Details Tocilizumab Everolimus Afinitor Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Fentanyl Transdermal Patch Duragesic® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Flecainide Tambocor® Reduced CYP2D6 substrate exposure and reduced efficacy of CYP2D6 substrate Details Tocilizumab Levonorgestrel After banger Reduced oral contraceptives exposure and reduced efficacy of oral contraceptives Details Tocilizumab Levonorgestrel Intrauterine System Kyleena Reduced oral contraceptives exposure and reduced efficacy of oral contraceptives Details Tocilizumab Lovastatin Altocor® Reduced lovastatin exposure and reduced efficacy of lovastatin Details Tocilizumab Mexiletine Mexitil® Reduced mexiletine exposure and reduced efficacy of mexiletine Details Tocilizumab Midostaurin Rydapt Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Neratinib Nerlynx Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Tocilizumab Olaparib Lynparza Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details

Moderate

Tocilizumab Clopidogrel Plavix Increased clopidogrel active metabolite exposure and an increased platelet inhibition Details